Literature DB >> 19671786

Immunogenetic studies on systemic lupus erythematosus.

G D Sebastiani1, M Galeazzi.   

Abstract

Understanding the pathogenesis of systemic lupus erythematosus (SLE) remains a considerable challenge. Multiple abnormalities of both the innate and adaptive immune system have been described and, furthermore, immunological dysfunction precedes clinical presentation by many years. There is a strong genetic basis to SLE, which means that genetic studies can play a key role in furthering our understanding of this disease. Because susceptibility variants are present from birth and are unaffected by the course of the disease, or by its treatment, genetic analysis is, perhaps uniquely, capable of identifying fundamental, causative, disease mechanisms. In this article, we review our SLE immunogenetic studies performed in collaboration with the European Working Party on Systemic Lupus Erythematosus. By considering the results of our research and the recent advances obtained by genome-wide associations' studies, we can begin to understand how dysregulation at a number of key immunological steps may predispose to the development of SLE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671786     DOI: 10.1177/0961203309106918

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

Review 1.  Interferon alpha in systemic lupus erythematosus.

Authors:  Timothy B Niewold; Daniel N Clark; Rafah Salloum; Brian D Poole
Journal:  J Biomed Biotechnol       Date:  2010-06-29

2.  Mayan alleles of the HLA-DRB1 major histocompatibility complex might contribute to the genetic susceptibility to systemic lupus erythematosus in Mexican patients from Tapachula, Chiapas.

Authors:  Rafael Garcia-Silva; Susana Hernandez-Doño; Jeniffer Patricia Román-Amparo; Ma Guadalupe Trujillo-Vizuet; Blanca Aurora Mena-Vela; Andrea Rizo-Pinto; José Manuel Pérez Tirado; José Hiram Cetina-Díaz; Pedro Bulos-Rodríguez; Julio Granados; Jesús Sepúlveda-Delgado
Journal:  Clin Rheumatol       Date:  2021-02-11       Impact factor: 2.980

3.  A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients.

Authors:  Julien Pothlichet; Timothy B Niewold; Damien Vitour; Brigitte Solhonne; Mary K Crow; Mustapha Si-Tahar
Journal:  EMBO Mol Med       Date:  2011-01-26       Impact factor: 12.137

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.